{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:44:22Z","timestamp":1776897862529,"version":"3.51.2"},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CDMRP BCRP 10578683"],"award-info":[{"award-number":["CDMRP BCRP 10578683"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["KG101475"],"award-info":[{"award-number":["KG101475"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Irwin Belk Endowment"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224309","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T18:31:11Z","timestamp":1573065071000},"page":"e0224309","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice"],"prefix":"10.1371","volume":"14","author":[{"given":"Jennifer M.","family":"Curry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahlia M.","family":"Besmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-2528","authenticated-orcid":true,"given":"Timothy K.","family":"Erick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nury","family":"Steuerwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lopamudra","family":"Das Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanti","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sritama","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-1040","authenticated-orcid":true,"given":"Jacob W.","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinku","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"issue":"1","key":"pone.0224309.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"RL Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9503","key":"pone.0224309.ref002","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","author":"M Clarke","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"pone.0224309.ref003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/joim.12084","article-title":"Breast cancer as a systemic disease: a view of metastasis","volume":"274","author":"AJ Redig","year":"2013","journal-title":"J Intern Med"},{"key":"pone.0224309.ref004","article-title":"Rationale for immunological approaches to breast cancer therapy","author":"GC Monnot","year":"2017","journal-title":"Breast"},{"issue":"2","key":"pone.0224309.ref005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coi.2004.01.012","article-title":"Current developments of immunotherapy in the clinic","volume":"16","author":"S Antonia","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"14","key":"pone.0224309.ref006","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-04-0347","article-title":"Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses","volume":"10","author":"D Avigan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"29","key":"pone.0224309.ref007","doi-asserted-by":"crossref","first-page":"28194","DOI":"10.18632\/oncotarget.4442","article-title":"A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model","volume":"6","author":"AR Kwilas","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0224309.ref008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"C Guo","year":"2013","journal-title":"Adv Cancer Res"},{"key":"pone.0224309.ref009","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"CL Hattrup","year":"2008","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"pone.0224309.ref010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"S Nath","year":"2014","journal-title":"Trends Mol Med"},{"issue":"25","key":"pone.0224309.ref011","doi-asserted-by":"crossref","first-page":"15286","DOI":"10.1016\/S0021-9258(18)77254-2","article-title":"Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin","volume":"265","author":"SJ Gendler","year":"1990","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0224309.ref012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00002371-200301000-00006","article-title":"Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer","volume":"26","author":"P Mukherjee","year":"2003","journal-title":"J Immunother"},{"issue":"2","key":"pone.0224309.ref013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.clbc.2012.09.016","article-title":"Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues","volume":"13","author":"SK Ghosh","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"pone.0224309.ref014","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.humpath.2013.04.010","article-title":"MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer","volume":"44","author":"A Siroy","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"pone.0224309.ref015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/002215540305100609","article-title":"Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer","volume":"51","author":"MV Croce","year":"2003","journal-title":"J Histochem Cytochem"},{"key":"pone.0224309.ref016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1476-4598-5-57","article-title":"MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression","volume":"5","author":"JZ Zaretsky","year":"2006","journal-title":"Mol Cancer"},{"issue":"17","key":"pone.0224309.ref017","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"MA Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"pone.0224309.ref018","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.vaccine.2006.11.007","article-title":"MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model","volume":"25","author":"P Mukherjee","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"pone.0224309.ref019","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4049\/jimmunol.182.1.216","article-title":"Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition","volume":"182","author":"P Mukherjee","year":"2009","journal-title":"J Immunol"},{"issue":"11\u201312","key":"pone.0224309.ref020","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1023\/A:1022260711583","article-title":"MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment","volume":"18","author":"P Mukherjee","year":"2001","journal-title":"Glycoconj J"},{"key":"pone.0224309.ref021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/BD-2004-20107","article-title":"Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model","volume":"20","author":"P Mukherjee","year":"2004","journal-title":"Breast Dis"},{"issue":"4","key":"pone.0224309.ref022","first-page":"655","article-title":"Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships","volume":"10","author":"A Zarghi","year":"2011","journal-title":"Iran J Pharm Res"},{"issue":"1","key":"pone.0224309.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.06.014","article-title":"Cyclooxygenases in cancer: progress and perspective","volume":"215","author":"S Zha","year":"2004","journal-title":"Cancer Lett"},{"issue":"6","key":"pone.0224309.ref024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00310-6","article-title":"Targeting cyclooxygenase-2 in human neoplasia: rationale and promise","volume":"4","author":"AJ Dannenberg","year":"2003","journal-title":"Cancer Cell"},{"issue":"7","key":"pone.0224309.ref025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma","volume":"202","author":"PC Rodriguez","year":"2005","journal-title":"J Exp Med"},{"key":"pone.0224309.ref026","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"B Liu","year":"2015","journal-title":"Cancer Cell Int"},{"issue":"12","key":"pone.0224309.ref027","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/01.MP.0000097372.73582.CB","article-title":"Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors","volume":"16","author":"JY Shim","year":"2003","journal-title":"Mod Pathol"},{"issue":"3","key":"pone.0224309.ref028","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1245\/ASO.2004.05.027","article-title":"Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer","volume":"11","author":"BA Pockaj","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"pone.0224309.ref029","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1749-6632.2000.tb06709.x","article-title":"Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer","volume":"910","author":"RA Gupta","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"pone.0224309.ref030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35094017","article-title":"Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2","volume":"1","author":"RA Gupta","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"pone.0224309.ref031","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1541-7786.632.2.11","article-title":"COX-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer","volume":"2","author":"GD Basu","year":"2004","journal-title":"Molecular Cancer Research"},{"issue":"4","key":"pone.0224309.ref032","doi-asserted-by":"crossref","first-page":"R422","DOI":"10.1186\/bcr1019","article-title":"Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells","volume":"7","author":"GD Basu","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"2","key":"pone.0224309.ref033","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"V. Jendrossek","year":"2013","journal-title":"Cancer Lett"},{"issue":"4","key":"pone.0224309.ref034","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.4049\/jimmunol.177.4.2391","article-title":"Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO","volume":"177","author":"GD Basu","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"pone.0224309.ref035","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","article-title":"Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation","volume":"164","author":"P Hwu","year":"2000","journal-title":"J Immunol"},{"issue":"22","key":"pone.0224309.ref036","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"J Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"key":"pone.0224309.ref037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"YW Moon","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"8","key":"pone.0224309.ref038","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/S0021-9258(17)35696-X","article-title":"Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase","volume":"261","author":"O Takikawa","year":"1986","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0224309.ref039","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14728222.9.4.831","article-title":"Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors","volume":"9","author":"AJ Muller","year":"2005","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"pone.0224309.ref040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"AJ Muller","year":"2005","journal-title":"Nat Med"},{"issue":"1","key":"pone.0224309.ref041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/156800907780006896","article-title":"Indoleamine 2,3-dioxygenase in immune suppression and cancer","volume":"7","author":"AJ Muller","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"10","key":"pone.0224309.ref042","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"C Uyttenhove","year":"2003","journal-title":"Nat Med"},{"issue":"7","key":"pone.0224309.ref043","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00262-006-0256-1","article-title":"Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression","volume":"56","author":"M Wobser","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"pone.0224309.ref044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"M Nakanishi","year":"2013","journal-title":"Semin Immunopathol"},{"issue":"10","key":"pone.0224309.ref045","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/0006-2952(95)02035-7","article-title":"6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist","volume":"50","author":"DF Woodward","year":"1995","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"pone.0224309.ref046","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/MCB.12.3.954","article-title":"Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease","volume":"12","author":"CT Guy","year":"1992","journal-title":"Mol Cell Biol"},{"issue":"2","key":"pone.0224309.ref047","first-page":"315","article-title":"Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model","volume":"58","author":"GJ Rowse","year":"1998","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0224309.ref048","first-page":"143","article-title":"Kinetic parameters and growth curves for experimental tumor systems","volume":"54","author":"L Simpson-Herren","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"pone.0224309.ref049","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.ph.57.030195.003135","article-title":"Epithelial mucin genes","volume":"57","author":"SJ Gendler","year":"1995","journal-title":"Annu Rev Physiol"},{"issue":"3\u20134","key":"pone.0224309.ref050","first-page":"536","article-title":"A tumor specific antibody to aid breast cancer screening in women with dense breast tissue","volume":"8","author":"LD Roy","year":"2017","journal-title":"Genes Cancer"},{"issue":"12","key":"pone.0224309.ref051","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/onc.2010.526","article-title":"MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition","volume":"30","author":"LD Roy","year":"2011","journal-title":"Oncogene"},{"issue":"6","key":"pone.0224309.ref052","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/MPA.0000000000000371","article-title":"Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer","volume":"44","author":"S Nath","year":"2015","journal-title":"Pancreas"},{"issue":"4","key":"pone.0224309.ref053","first-page":"295","volume":"9","author":"LJ Moore","year":"2016","journal-title":"Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors. Transl Oncol"},{"issue":"2","key":"pone.0224309.ref054","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","article-title":"A comparison of normalization methods for high density oligonucleotide array data based on variance and bias","volume":"19","author":"BM Bolstad","year":"2003","journal-title":"Bioinformatics"},{"issue":"2","key":"pone.0224309.ref055","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr3412","article-title":"Arthritis augments breast cancer metastasis: role of mast cells and SCF\/c-Kit signaling","volume":"15","author":"LD Roy","year":"2013","journal-title":"Breast Cancer Res"},{"key":"pone.0224309.ref056","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/1471-2407-11-365","article-title":"Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer","volume":"11","author":"LD Roy","year":"2011","journal-title":"BMC Cancer"},{"issue":"8","key":"pone.0224309.ref057","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.4049\/jimmunol.179.8.5474","article-title":"The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment","volume":"179","author":"AL Coelho","year":"2007","journal-title":"J Immunol"},{"key":"pone.0224309.ref058","first-page":"948098","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"NB Hao","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"pone.0224309.ref059","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: an emerging key player in the mammalian immune system","volume":"158","author":"M. Munder","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"3","key":"pone.0224309.ref060","first-page":"201","article-title":"Immune function of the decoy receptor osteoprotegerin","volume":"22","author":"AK Bengtsson","year":"2002","journal-title":"Crit Rev Immunol"},{"issue":"23","key":"pone.0224309.ref061","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"JG Emery","year":"1998","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0224309.ref062","first-page":"59","article-title":"regulate breast cancer progression","volume":"33","author":"J O'Kelly","year":"2008","journal-title":"Int J Oncol"},{"issue":"1","key":"pone.0224309.ref063","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12079-013-0214-6","article-title":"CCN1 promotes vascular endothelial growth factor secretion through alphavbeta 3 integrin receptors in breast cancer","volume":"8","author":"I Espinoza","year":"2014","journal-title":"J Cell Commun Signal"},{"issue":"11","key":"pone.0224309.ref064","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ejca.2005.04.023","article-title":"Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer","volume":"41","author":"AM Burger","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0224309.ref065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/2326-6066.CIR-18-0256","article-title":"Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid","volume":"7","author":"N Stergiou","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"pone.0224309.ref066","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.vaccine.2019.02.055","article-title":"Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response","volume":"37","author":"H Zhang","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"pone.0224309.ref067","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1505","article-title":"Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]","volume":"8","author":"V Apostolopoulos","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"11","key":"pone.0224309.ref068","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2217\/imt.13.126","article-title":"Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1","volume":"5","author":"S Vassilaros","year":"2013","journal-title":"Immunotherapy"},{"issue":"8","key":"pone.0224309.ref069","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"D Miles","year":"2011","journal-title":"Oncologist"},{"issue":"8","key":"pone.0224309.ref070","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/blood-2004-04-1294","article-title":"Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity","volume":"104","author":"P Mirandola","year":"2004","journal-title":"Blood"},{"issue":"2","key":"pone.0224309.ref071","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","article-title":"Following TRAIL's path in the immune system","volume":"127","author":"C Falschlehner","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"pone.0224309.ref072","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.193.6.661","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis","volume":"193","author":"MJ Smyth","year":"2001","journal-title":"J Exp Med"},{"issue":"1","key":"pone.0224309.ref073","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/83416","article-title":"Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells","volume":"7","author":"K Takeda","year":"2001","journal-title":"Nat Med"},{"issue":"4","key":"pone.0224309.ref074","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160150","article-title":"RANK-RANKL signalling in cancer","volume":"36","author":"N Renema","year":"2016","journal-title":"Biosci Rep"},{"issue":"6","key":"pone.0224309.ref075","first-page":"1619","article-title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells","volume":"62","author":"I Holen","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"pone.0224309.ref076","doi-asserted-by":"crossref","first-page":"1681S","DOI":"10.1093\/jn\/137.6.1681S","article-title":"Arginine and immunity","volume":"137","author":"PJ Popovic","year":"2007","journal-title":"J Nutr"},{"issue":"2","key":"pone.0224309.ref077","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","article-title":"l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells","volume":"75","author":"M Fletcher","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"pone.0224309.ref078","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"V Bronte","year":"2003","journal-title":"Trends Immunol"},{"issue":"2","key":"pone.0224309.ref079","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12032-011-9873-4","article-title":"HLA class-II allele frequencies in Turkish breast cancer patients","volume":"29","author":"FD Gun","year":"2012","journal-title":"Med Oncol"},{"issue":"1","key":"pone.0224309.ref080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12253-011-9415-6","article-title":"HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer","volume":"18","author":"M Mahmoodi","year":"2012","journal-title":"Pathol Oncol Res"},{"issue":"49","key":"pone.0224309.ref081","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1038\/onc.2016.161","article-title":"A CCL8 gradient drives breast cancer cell dissemination","volume":"35","author":"E Farmaki","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"pone.0224309.ref082","doi-asserted-by":"crossref","first-page":"12664","DOI":"10.18632\/oncotarget.8610","article-title":"CD74 and intratumoral immune response in breast cancer","volume":"8","author":"ZQ Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"pone.0224309.ref083","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.4049\/jimmunol.169.7.3876","article-title":"The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte\/macrophage and neutrophil lineages","volume":"169","author":"PR Taylor","year":"2002","journal-title":"J Immunol"},{"key":"pone.0224309.ref084","first-page":"e04177","article-title":"Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses","volume":"3","author":"S Chiba","year":"2014","journal-title":"ElifePubMed Central PMCID"},{"issue":"53","key":"pone.0224309.ref085","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1038\/sj.onc.1205682","article-title":"Cyr61 promotes breast tumorigenesis and cancer progression","volume":"21","author":"MS Tsai","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"pone.0224309.ref086","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.18632\/oncotarget.13677","article-title":"The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis","volume":"8","author":"YT Huang","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0224309.ref087","doi-asserted-by":"crossref","first-page":"638526","DOI":"10.1155\/2015\/638526","article-title":"Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer","volume":"2015","author":"KA Marzec","year":"2015","journal-title":"Biomed Res Int"},{"issue":"8","key":"pone.0224309.ref088","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/bjc.1996.523","article-title":"Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer","volume":"74","author":"H Yu","year":"1996","journal-title":"Br J Cancer"},{"issue":"4","key":"pone.0224309.ref089","first-page":"1131","article-title":"Insulin-like growth factor-binding protein-3 in breast cancer: analysis with tissue microarray","volume":"29","author":"SM Sheen-Chen","year":"2009","journal-title":"Anticancer Res"},{"issue":"10","key":"pone.0224309.ref090","first-page":"3785","article-title":"The expression and function of IGFBP-3 in normal and malignant breast tissue","volume":"29","author":"K McCarthy","year":"2009","journal-title":"Anticancer Res"},{"issue":"4","key":"pone.0224309.ref091","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.190.4.445","article-title":"The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs","volume":"190","author":"SJ Shiff","year":"1999","journal-title":"J Exp Med"},{"issue":"4","key":"pone.0224309.ref092","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1084\/jem.190.4.451","article-title":"Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts","volume":"190","author":"X Zhang","year":"1999","journal-title":"J Exp Med"},{"issue":"3","key":"pone.0224309.ref093","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-8674(00)81664-5","article-title":"PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs","volume":"99","author":"TC He","year":"1999","journal-title":"Cell"},{"issue":"7","key":"pone.0224309.ref094","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/0008-5472.CAN-06-3431","article-title":"Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon","volume":"67","author":"JY Liou","year":"2007","journal-title":"Cancer Res"},{"key":"pone.0224309.ref095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2013.00181","article-title":"COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs","volume":"3","author":"E Gurpinar","year":"2013","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0224309.ref096","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.bjc.6602942","article-title":"COX inhibitors and breast cancer","volume":"94","author":"D Mazhar","year":"2006","journal-title":"Br J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T20:56:00Z","timestamp":1664830560000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224309"}},"subtitle":[],"editor":[{"given":"Pankaj K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224309","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]}}}